



www.cgen.com

Contact:
Ms Tsipi Keren Lehrer
 tsipikl@compugen.co.il

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. The Company's primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies.



Success Story of Compugen Ltd.



www.smesgolifesciences.org

EU FP Project : RIBOSYS **RiboSys**

Project Title: Systems Biology of RNA Metabolism in Yeast

Call details:

Priority : LSH
 Submission date : 16.11.2004
 Reference : LSH-2004-1.1.0-1

Project type:

Integrated Project
 Network of Excellence
 ● Specific Targeted Research Project

Website: www.ribosys.org

Project Abstract:

The RiboSys project will use systems biology approaches to model pre-messenger RNA and pre-ribosomal RNA metabolism in *Saccharomyces cerevisiae* and so aid understanding of these complex cellular pathways. The RiboSys project will develop a notation system that permits RNA molecules to be described in a universal format, comparable between different species and organisms, and that is also compatible with a mathematical description.

Consortium composition : 6 partners from 6 countries

University of Edinburgh	UK	Warsaw University	PL
Institut de Génétique Moléculaire de Montpellier (IGMM) CNRS	FR	European Molecular Biology Laboratory	DE
SME Compugen Ltd	IL	Biosystems Informatics Institute SPb Company Limited	RU
Universität Zürich	CH		

Compugen in RIBOSYS

Compugen role in the Project is quantitative modeling of the pre-mRNA metabolism pathway in Yeast

Dr. Alex Kotzer, CEO, Compugen says, "We decided to apply to the program in order to increase our exposure to new technology and to enhance the development of internal discovery tools."

Compugen's **expectation** from the consortium are:

- Gain access to experimental data sources in order to develop tools to analyze them
- Enable comparison between models
- Collaboration & networking

Intellectual Property Rights (IPR) are taken care of in the Consortium agreements.

SMEs go LifeSciences partner (ISERD) assisted Compugen in various ways such as aspects of the submission procedure, the forms and paperwork, and most importantly, was available for consultation on all sorts of administrative and IPR questions.

Compugen is a coordinator of another EU FP project, SIMAP, a consortium for the development of a platform to simulate the MAP-kinase pathway, a signaling pathway related to cancer which is already targeted by a number of cancer therapies and diagnostic tests.

SMEs go LifeSciences partner :

ISERD - www.iserd.org.il
Contact Person : Dr. Eva Rockman - eva@iserd.org.il

SMEs go LifeSciences is co-funded by the European Commission

